Top

International Journal of Colorectal Disease

Published in:

Open Access 01-02-2019 | Original Article

Soluble intercellular adhesion molecule-1 is a prognostic marker in colorectal carcinoma

Authors: Vera S. Schellerer, Melanie C. Langheinrich, Veronika Zver, Robert Grützmann, Michael Stürzl, Olaf Gefeller, Elisabeth Naschberger, Susanne Merkel

Published in: International Journal of Colorectal Disease | Issue 2/2019

Abstract

Purpose

Serological tumor markers are routinely used to monitor tumor onset and progression. In colorectal carcinoma (CRC), the carcinoembryonic antigen (CEA) is roughly elevated in 50% of patients at initial diagnosis. Soluble ICAM-1 (sICAM-1) is elevated in different cancers. The aim of this study was to evaluate the prognostic relevance of sICAM-1 combined with CEA in patients with CRC.

Methods

In blood samples of 297 CRC patients, sICAM-1 was determined by ELISA and CEA by microparticle enzyme immunoassay the day before oncologic resection. Separation in patients with sICAM-1^high and sICAM-1^low was performed by minimum p value approach; separation in CEA normal and elevated was performed according to the established diagnostic cutoff. Clinical data were obtained from the prospective collected data from the Erlangen Registry for Colorectal Carcinomas.

Results

Cancer-related 5-year survival rate of patients with sICAM-1^low (< 290 ng/ml, n = 208) was significantly increased (83.4%) as compared to that of patients with sICAM-1^high (≥ 290 ng/ml, n = 89) (66.2%; p < 0.001). Patients with normal CEA concentrations (n = 199; 90.8%) showed a significantly (p < 0.001) improved cancer-related 5-year survival rate compared to patients with elevated CEA concentrations (n = 98; 52.1%). Moreover, high sICAM-1 was an independent risk factor (hazard ratio 1.6) in multivariate analysis. Of note, increased sICAM-1 levels, either within normal or within elevated CEA, allowed to identify high-risk subgroups, both for overall (p < 0.001) and cancer-related survival (p < 0.001).

Conclusion

Application of a novel risk score combining CEA/sICAM-1 serum concentrations allows the identification of high-risk groups for poor survival in CRC patients.

Torre LA, Siegel RL, Ward EM, Jemal A (2016) Global cancer incidence and mortality rates and trends--an update. Cancer Epidemiol Biomark Prev 25(1):16–27. https://doi.org/10.1158/1055-9965.EPI-15-0578 CrossRef

Lech G, Slotwinski R, Slodkowski M, Krasnodebski IW (2016) Colorectal cancer tumour markers and biomarkers: recent therapeutic advances. World J Gastroenterol 22(5):1745–1755. https://doi.org/10.3748/wjg.v22.i5.1745 CrossRefPubMedPubMedCentral

Campos-da-Paz M, Dorea JG, Galdino AS, Lacava ZGM, Almeida Santos MFM (2018) Carcinoembryonic antigen (CEA) and hepatic metastasis in colorectal cancer: update on biomarker for clinical and biotechnological approaches. Recent Pat Biotechnol. https://doi.org/10.2174/1872208312666180731104244

Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C, Topolcan O (2007) Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 43(9):1348–1360. https://doi.org/10.1016/j.ejca.2007.03.021 CrossRefPubMed

Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2017) S3-Leitlinie Kolorektales Karzinom, Langversion 2.0, AWMF Registrierungsnummer: 021/007OL, http://www.leitlinienprogramm-onkologie.de/leitlinien/kolorektales-karzinom/. Accessed 4 Feb 2018

Bannura G, Cumsille MA, Contreras J, Barrera A, Melo C, Soto D (2004) Carcinoembryonic antigen (CEA) as an independent prognostic factor in colorectal carcinoma. Rev Med Chil 132(6):691–700CrossRefPubMed

Chen CC, Yang SH, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Chang SC (2005) Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? J Surg Res 124(2):169–174. https://doi.org/10.1016/j.jss.2004.08.013 CrossRefPubMed

Boras Z, Kondza G, Sisljagic V, Busic Z, Gmajnic R, Istvanic T (2012) Prognostic factors of local recurrence and survival after curative rectal cancer surgery: a single institution experience. Coll Antropol 36(4):1355–1361PubMed

Bruinvels DJ, Stiggelbout AM, Kievit J, van Houwelingen HC, Habbema JD, van de Velde CJ (1994) Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg 219(2):174–182CrossRefPubMedPubMedCentral

10.

Graham RA, Wang S, Catalano PJ, Haller DG (1998) Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy. Ann Surg 228(1):59–63CrossRefPubMedPubMedCentral

11.

Carpelan-Holmstrom M, Haglund C, Lundin J, Jarvinen H, Roberts P (1996) Pre-operative serum levels of CA 242 and CEA predict outcome in colorectal cancer. Eur J Cancer 32A(7):1156–1161CrossRefPubMed

12.

Wang JY, Tang R, Chiang JM (1994) Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon Rectum 37(3):272–277CrossRefPubMed

13.

Lucha PA Jr, Rosen L, Olenwine JA, Reed JF 3rd, Riether RD, Stasik JJ Jr, Khubchandani IT (1997) Value of carcinoembryonic antigen monitoring in curative surgery for recurrent colorectal carcinoma. Dis Colon Rectum 40(2):145–149CrossRefPubMed

14.

Quentmeier A, Schlag P, Hohenberger P, Schwarz V, Abel U (1989) Assessment of serial carcinoembryonic antigen: determinations to monitor the therapeutic progress and prognosis of metastatic liver disease treated by regional chemotherapy. J Surg Oncol 40(2):112–118CrossRefPubMed

15.

Benson V, McMahon AC, Lowe HC (2007) ICAM-1 in acute myocardial infarction: a potential therapeutic target. Curr Mol Med 7(2):219–227CrossRefPubMed

16.

Niessen HW, Lagrand WK, Visser CA, Meijer CJ, Hack CE (1999) Upregulation of ICAM-1 on cardiomyocytes in jeopardized human myocardium during infarction. Cardiovasc Res 41(3):603–610CrossRefPubMed

17.

Huang WC, Chan ST, Yang TL, Tzeng CC, Chen CC (2004) Inhibition of ICAM-1 gene expression, monocyte adhesion and cancer cell invasion by targeting IKK complex: molecular and functional study of novel alpha-methylene-gamma-butyrolactone derivatives. Carcinogenesis 25(10):1925–1934. https://doi.org/10.1093/carcin/bgh211 CrossRefPubMed

18.

Witkowska AM, Borawska MH (2004) Soluble intercellular adhesion molecule-1 (sICAM-1): an overview. Eur Cytokine Netw 15(2):91–98PubMed

19.

Schellerer VS, Langheinrich M, Hohenberger W, Croner RS, Merkel S, Rau TT, Sturzl M, Naschberger E (2014) Tumor-associated fibroblasts isolated from colorectal cancer tissues exhibit increased ICAM-1 expression and affinity for monocytes. Oncol Rep 31(1):255–261. https://doi.org/10.3892/or.2013.2860 CrossRefPubMed

20.

Alexiou D, Karayiannakis AJ, Syrigos KN, Zbar A, Sekara E, Michail P, Rosenberg T, Diamantis T (2003) Clinical significance of serum levels of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in gastric cancer patients. Am J Gastroenterol 98(2):478–485. https://doi.org/10.1111/j.1572-0241.2003.07259.x CrossRefPubMed

21.

Alexiou D, Karayiannakis AJ, Syrigos KN, Zbar A, Kremmyda A, Bramis I, Tsigris C (2001) Serum levels of E-selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: correlations with clinicopathological features, patient survival and tumour surgery. Eur J Cancer 37(18):2392–2397CrossRefPubMed

22.

Christiansen I, Sundstrom C, Totterman TH (1998) Elevated serum levels of soluble vascular cell adhesion molecule-1 (sVCAM-1) closely reflect tumour burden in chronic B-lymphocytic leukaemia. Br J Haematol 103(4):1129–1137CrossRefPubMed

23.

O'Hanlon DM, Fitzsimons H, Lynch J, Tormey S, Malone C, Given HF (2002) Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma. Eur J Cancer 38(17):2252–2257CrossRefPubMed

24.

Perabo F, Sharma S, Gierer R, Wirger A, Fimmers R, Steiner G, Adam M, Schultze-Seemann W (2001) Circulating intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin in urological malignancies. Indian J Cancer 38(1):1–7PubMed

25.

Pasieka Z, Kuzdak K, Czyz W, Stepien H, Komorowski J (2004) Soluble intracellular adhesion molecules (sICAM-1, sVCAM-1) in peripheral blood of patients with thyroid cancer. Neoplasma 51(1):34–37PubMed

26.

Yamada M, Yanaba K, Takehara K, Sato S (2005) Clinical significance of serum levels of soluble intercellular adhesion molecule-1 and soluble L-selectin in malignant melanoma. Arch Dermatol Res 297(6):256–260. https://doi.org/10.1007/s00403-005-0605-5 CrossRefPubMed

27.

Markocka-Maczka K (2003) Concentration of serum soluble forms of ICAM-1 (sVCAM-1) and VCAM-1 (sVCAM-1) in patients with chronic pancreatitis and in patients with pancreatic carcinoma. Wiadomosci lekarskie 56(3–4):147–151PubMed

28.

Basoglu M, Yildirgan MI, Taysi S, Yilmaz I, Kiziltunc A, Balik AA, Celebi F, Atamanalp SS (2003) Levels of soluble intercellular adhesion molecule-1 and total sialic acid in serum of patients with colorectal cancer. J Surg Oncol 83(3):180–184. https://doi.org/10.1002/jso.10257 CrossRefPubMed

29.

Kang X, Wang F, Xie JD, Cao J, Xian PZ (2005) Clinical evaluation of serum concentrations of intercellular adhesion molecule-1 in patients with colorectal cancer. World J Gastroenterol 11(27):4250–4253CrossRefPubMedPubMedCentral

30.

Mantur M, Snarska J, Koper O, Dzieciol J, Plonski A, Lemancewicz D (2009) Serum sICAM, sVCAM and sE-selectin levels in colorectal cancer patients. Folia Histochem Cytobiol 47(4):621–625. https://doi.org/10.2478/v10042-009-0077-0 CrossRefPubMed

31.

Nakata B, Hori T, Sunami T, Ogawa Y, Yashiro M, Maeda K, Sawada T, Kato Y, Ishikawa T, Hirakawa K (2000) Clinical significance of serum soluble intercellular adhesion molecule 1 in gastric cancer. Clin Cancer Res 6(3):1175–1179PubMed

32.

Tsakadze NL, Sithu SD, Sen U, English WR, Murphy G, D'Souza SE (2006) Tumor necrosis factor-alpha-converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1). J Biol Chem 281(6):3157–3164. https://doi.org/10.1074/jbc.M510797200 CrossRefPubMed

33.

Gearing AJ, Newman W (1993) Circulating adhesion molecules in disease. Immunol Today 14(10):506–512. https://doi.org/10.1016/0167-5699(93)90267-O CrossRefPubMed

34.

Gho YS, Kleinman HK, Sosne G (1999) Angiogenic activity of human soluble intercellular adhesion molecule-1. Cancer Res 59(20):5128–5132PubMed

35.

Brierly J, Gospodarowicz M, Wittekind CE (2017) TNM classification of malignant tumors, 8th edn. Wiley Blackwell, Oxford

36.

Greenwood M (1926) The errors of sampling of the survivorship table reports on public health and medical subjects, vol 33. Her Majesty’s Stationery Office, London

37.

Giessen C, Nagel D, Glas M, Spelsberg F, Lau-Werner U, Modest DP, Michl M, Heinemann V, Stieber P, Schulz C (2014) Evaluation of preoperative serum markers for individual patient prognosis in stage I-III rectal cancer. Tumour Biol 35(10):10237–10248. https://doi.org/10.1007/s13277-014-2338-6 CrossRefPubMed

Title: Soluble intercellular adhesion molecule-1 is a prognostic marker in colorectal carcinoma
Authors: Vera S. Schellerer
Melanie C. Langheinrich
Veronika Zver
Robert Grützmann
Michael Stürzl
Olaf Gefeller
Elisabeth Naschberger
Susanne Merkel
Publication date: 01-02-2019
Publisher: Springer Berlin Heidelberg
Published in: International Journal of Colorectal Disease / Issue 2/2019
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-018-3198-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Soluble intercellular adhesion molecule-1 is a prognostic marker in colorectal carcinoma

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2019

Optimal time for single-stage pull-through colectomy in infants with short-segment Hirschsprung disease

The effect of pasireotide on intestinal anastomotic healing with and without whole-body irradiation in a rat model

Accuracy of diagnostic tests and a new algorithm for diagnosing cytomegalovirus colitis in inflammatory bowel diseases: a diagnostic study

Trends and outcomes of sphincter-preserving surgery for rectal cancer: a national cancer database study

Focus on current and future management possibilities in inflammatory bowel disease-related chronic pain

Outcome disparities in colorectal cancer: a SEER-based comparative analysis of racial subgroups